- Trial phase
- Approved
- Time to market
- Already approved and marketed since October 2020.
- Why 3/10
- Veklury is already FDA-approved and commercialized with no pending PDUFA, pivotal readout, or label-expansion decision in the next 12 months. It is a small and declining part of Gilead's business (Q3 2026 sales of $86 million, down 69% YoY, versus total company product sales of $8.3 billion). Per the rubric, an approved drug with no imminent binary catalyst scores 3-5, and the low revenue contribution anchors it at 3.
Veklury has no upcoming binary catalysts and is a negligible part of Gilead's business. For GILD investors, the focus should remain on the HIV franchise (which grew 18% in Q3 2026), the oncology portfolio including Trodelvy, and the newly launched twice-yearly PrEP drug Yeztugo. Veklury's continued revenue decline is already well-telegraphed and priced in.
Price Chart
Executive Summary
Veklury (remdesivir) is Gilead Sciences' FDA-approved intravenous antiviral for COVID-19, first approved in October 2020. As the pandemic has receded, Veklury sales have fallen sharply: $86 million in Q3 2026 (down 69% YoY), with full-year 2026 guidance cut to roughly $300 million from an initial $600 million. For context, Gilead's total Q3 2026 product sales were $8.3 billion, driven by its HIV franchise, Trodelvy, and Livdelzi. Veklury is now a minor, declining revenue contributor with no upcoming regulatory catalysts. The drug faces competition from oral alternatives like Pfizer's Paxlovid. Gilead's stock is driven by its HIV and oncology portfolios, not Veklury.
How It Works
Veklury is an antiviral drug given through an IV that blocks the virus's ability to copy its genetic material inside human cells. It was one of the first treatments approved for COVID-19 and is used mainly in hospitalized patients.
Trial Status
Veklury received full FDA approval in October 2020 for treating COVID-19 in hospitalized patients requiring supplemental oxygen. It was previously used under emergency use authorization. Gilead has also studied it in vulnerable patient populations including those with severe renal impairment and immunocompromised patients, with real-world evidence supporting reduced mortality and readmission rates across all variants including Omicron.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for Veklury specifically. Gilead is developing obeldesivir (GS-5245), an oral prodrug of the same parent nucleoside, as a potential next-generation COVID-19 treatment, but that is a separate molecule.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GILEAD SCIENCES, INC. 8-K GILD ·Originating report